Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Thursday, July 2

LAPOSTER SESSIONS TrackA 41208 -41235

41208 High prevalence ofprotease resistance mutations in therapy-naive HIV-1
positive German seroconvertors irrespective of viral subtype
Ursula Dietrich*; H. Knechten; H. Jdger; R. Husak; H. Ruppach;
H. von Briesen, Germany
41209 Rapid phenotypic detection of HIV-1 resistance to lamivudine (3TC) and
nevirapine (NVP) by direct analysis of plasma reverse transcriptase
activity
Walid Heneine*;J.G. Garcia-Lerma;J.G. Vasquez-Rosales; H. HavlirD.;
R.F. Schnazi; D.D. Richman; T.M. Folks, USA
41210 Genotypic prevalence of transmitted ZDV-and ddi-Resistant HIV-1
variants and natural polymorphism in protease coding region of
seroconverters
Claudia Balotta*;M. Violin; A. Berlusconi; A. Gori; S. Rusconi; M. Galli;
M. Moroni, Italy
41211 In vitro drug susceptibility and sequence analysis of HIV-1 group M
isolates belonging to different subtypes
Diane Descamps*; C Apetrei; G. Collin; I. Lousset-Ajaka; F. Damond;
F. Simon; F. Brun-Vezinet, France
41212 A resistance surmountable HIV protease inhibitor effective against both
wild-type and new analogs of HIV-1 protease
Yoshiaki Kiso*; M. Kishida; H. Matsumoto; S. Mizumoto; T. Kimura, Japan
41213 Virologic Resistance to efavirenz
Lee Bacheler*; 0. Weislow; S. Snyder; G. Hanna, USA
41214 HIV-1 expressing the 3TC-associated M184V mutation in Reverse
Transcriptase (RT) shows increased sensitivity to Adefovir and PMPA as
well as decreased replication capacity in vitro
Michael Miller*; K.E. Anton; A.S. Mulato; P.D. Lamy; N.A. Margot;
J.M. Cherrington, USA
41215 Nelfinavirin HAART-experienced HIV-1 infected patients:
Prediction of response by protease genotyping
Patrizio Lorenzi*; J.P. Chaves; L. Kaiser; B. Hirschel; L. Perrin; S. Yerly;
Swiss HIV Cohort Study, Switzerland
41216 A comparison of sequencing and a reverse hybridisation assay (LiPA)
for the detection of mutations in the RT gene of HIV-1
Colin Evans*; D. Parker; F. Sheridan;J. Scott; G. Wouters; L. Styuver;
A. Van Den Abeele, UK
41217 Comparison ofprotease mutations in HIV-1 genomes detected in plasma
and blood mononuclear cells
Catherine Tamalet*; Nathalie Koch; N. Yahi; F. Ariasi;J. Fantini, France
41218 Genotypic changes in HIV RT which develop during PreveonT (Adefovir
Dipivoxil) therapy do not decrease susceptibility to PMPA
Michael Miller*; J.M. Cherrington; P.D. Lamy; A.S. Mulato; K.E. Anton;
N.A. Margot, USA
41219 Line Probe Assay compared with clonal and population-based
sequencing for detection of resistance mutations in HIV-1 RT
Marlene M. Rayner*; J. Meek; R. Bidwell; K. Abremski; G. Hollis;
S. Erickson-Viitanen; L. Bacheler, USA
41220 Assessment of the Line Probe Assay in the detection of nucleoside
analogue resistance in a HIV-infected paedriatric cohort
Marek Slomka*; F. Sheridan; S. Muckelt; D. Parker; S.E. Read; S. Cassol;
S. King, UK

41221 Pattern of drug resistance in HIV population
Paola Corsi*; M. Pozzi; M. Zazzi; G. Buffini; L. Incandela; E. Savalli;
F. Leoncini, Italy
41222 Impact of protease gene mutations on virological response to nelfinavir
Eva Wolf*; S. Mauss; R. Pascucci; A. Immelmann; U. Dietrich;
E. Jaegel-Guedes; H. Jaeger, Germany
41223 Novel clinical applications of the LiPA HIV-1 RT mutation detection assay
Colin Evans*; D. Parker; F. Sheridan; J. Scott; G. Wouters; L. Styuver;
A. van den Abeele, UK
41224 Emergence of drug-resistant HIV-1 strains from patients on long term
ddltherapy
Stephen Delaney*; N.N. Zheng; P. W. McQueen; D.A. Cooper, Australia
41225 Semi-quantitative HIV-1 mutation analysis using the Murex-lnnogenetics
Lipa HIV-1 RTassay
Fran Sheridan*; D. Parker; R. Shuurman; L. De Graaf;J. Tijnagel;
C. Boucher, UK
41226 Susceptibility profile (AntivirogramT) of 945 clinical HIV-1 isolates
to abacavir
Rudi Pauwels*; K. Hertogs; F. Peeters; R. Lanier; N. Graham; J. Mellors;
P. Stoffels, Belgium
41227 First study on resistance profile in a group of drug naive
patients in Argentina
Horacio E. Salomon*; Carlos M. Rossi; S.E. Pampuro; G.H. Kijak;
M.B. Lasala; G. Reboredo; 0. Libonatti; M. T. France Fernandez, Argentina
41228 Effect of haart +/- IL-2 on viral kinetics and T cell reconstitution in
lymphoid tissues of asymptomatic HIV-1 infected patients
Jan Van Lunzen*; K. Tenner-Racs; P. Racz; F. T. Hufert;. Lauer;
H.J. Stellbrink, Germany
41229 IL2 in HIV patients: A randomized trial comparing SC, PEG, CIV IL2
with AZT+ddl
Yves Levy*; C. Capitant; S. Houhou; I. Carriere; J.A. Gaustaut; J.P. Viard;
J.P. Aboulker, France
41230 Long-term follow-up of an early HIV-infected cohort receiving
intermittent outpatient treatment with subcutaneous
interleukin-2 (sclL-2)
Richard Davey, Jr.*; D.G. Chaitt; J.A. Kovacs; R.E. Walker; J. Falloon;
M.A. Polls; H.C. Lane, USA
41231 Efficacy of aminooxypentane (AOP)-RANTES as inhibitor of HIV-1
infectivity without impairment of cellular proliferation
Stefano Rusconi*; M. Clerici;S. Kurtagic; 5. La Seta-Catamancio;
D. Arienti; D. Trabattoni; M. Galli, Italy
41232 Xenogeneic porcine thymic transplantation for the treatment of AIDS
Boris Nikolic*; K.S. Stanley; M. Sykes, USA
41233 Characterization ofT cell expressed chimeric receptors with antibodytype specificity for the CD4 binding site of HIV-1 gp120
Natacha Bitton*; P. Debre; G. Gorochov, France
41234 CD38 stimulation exerts antiviral effects and modulates CXCR-4
expression in lymphoid cells
Liliana Calosso*; A. Savarino; A. Pugliese; F. Malavasi, Italy
41235 Interleukin-2 (IL-2) treatment reduces soluble CD30 (sCD30) plasma levels

and the percentage of apoptotic cells in HIV-infected patients
Cecilia Simonelli*; S. Zanussi; M. Dandrea; M.T. Bartolin; U. Tirelli;
P De Paoli, Italy

190

12th World AIDS Conference Geneva